Reneo Pharmaceuticals Earns Buy Rating from Analysts at HC Wainwright
RPHMDelisted Stock | USD 18.20 1.40 8.33% |
About 55% of Reneo Pharmaceuticals' investors are presently thinking to get in. The analysis of current outlook of investing in Reneo Pharmaceuticals suggests that some traders are interested regarding Reneo Pharmaceuticals' prospects. Reneo Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Reneo Pharmaceuticals. Many technical investors use Reneo Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Reneo |
HC Wainwright started coverage on shares of Reneo Pharmaceuticals in a research report report published on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a 30.00 price objective on the stock. HC Wainwright also issued estimates for Reneo Pharmaceuticals Q3 2023 earnings at EPS, Q4 2023
Read at thelincolnianonline.com
Reneo Pharmaceuticals Fundamental Analysis
We analyze Reneo Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reneo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reneo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Reneo Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Reneo Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Reneo Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Reneo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reneo Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Reneo Pharmaceuticals Related Equities
CNSP | Cns Pharmaceuticals | 5.45 | ||||
PRME | Prime Medicine, | 5.07 | ||||
CGEM | Cullinan Oncology | 3.99 | ||||
CELC | Celcuity LLC | 2.79 | ||||
CCCC | C4 Therapeutics | 2.58 | ||||
NKTX | Nkarta | 2.55 | ||||
KZR | Kezar Life | 2.13 | ||||
HOWL | Werewolf Therapeutics | 1.95 | ||||
RPRX | Royalty Pharma | 0.67 | ||||
ADPT | Adaptive Biotechnologies | 0.00 | ||||
SMMT | Summit Therapeutics | 0.00 | ||||
LEGN | Legend Biotech | 0.06 | ||||
HEPA | Hepion Pharmaceuticals | 0.20 | ||||
VIR | Vir Biotechnology | 0.41 | ||||
IMMX | Immix Biopharma | 0.92 | ||||
DNA | Ginkgo Bioworks | 0.95 | ||||
APLS | Apellis Pharmaceuticals | 1.11 | ||||
EWTX | Edgewise Therapeutics | 1.20 | ||||
KRON | Kronos Bio | 3.16 | ||||
OCEA | Ocean Biomedical | 3.22 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |